DeCure for Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immune dysregulation-polyendocrinopathy-enteropathy-x-linked syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
forkhead box P3 (FOXP3) — FOXP3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3QRF · 2.8 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is a rare monogenic disease in which an overactive immune system, driven by autoaggressive T cells and autoantibody-producing B cells, directly produces the clinical phenotype. Without prompt diagnosis and treatment the disease can be fatal within one year. A 2023 case report describes an infant with IPEX who developed vitiligo, alopecia, and chronic diarrhoea; while awaiting stem cell transplant he had multiple episodes of sepsis and died at 10 months of age. The same report states that early haematopoietic stem cell transplantation is the only cure for IPEX patients.
Earlier review articles from 2008 and 2009 note that studies of monogenic autoimmune diseases including IPEX have helped reveal the role of key regulators in the maintenance of immune tolerance. The 2008 review mentions that new agents are being tested for potentially treating and reversing the underlying autoimmune process in endocrine autoimmunity, but it does not name any specific drug or report any clinical trial results for IPEX. The 2009 review on disorders of immune regulation describes the discovery of monogenic defects in these disorders but provides no treatment data.
No drug therapy for IPEX is described in any of these abstracts. The only curative intervention mentioned is haematopoietic stem cell transplantation, and the single patient outcome reported is death before transplant could be completed. What remains missing are controlled trials of any pharmacological agent, a standardised approach to early diagnosis that reliably prevents fatal sepsis, and sufficient patient numbers to test stratified treatment strategies in this rare syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Endocrinology & Metabolism · 2008 · 39 citations · open access
Update in Endocrine Autoimmunity
AbstractCONTEXT: The endocrine system is a common target in pathogenic autoimmune responses, and there has been recent progress in our understanding, diagnosis, and treatment of autoimmune endocrine diseases. SYNTHESIS: Rapid progress has recently been made in our understanding of the genetic factors involved in endocrine autoimmune diseases. Studies on monogenic autoimmune diseases that include endocrine phenotypes like autoimmune polyglandular syndrome type 1 and immune dysregulation, polyendocrinopathy, enteropathy, X-linked have helped reveal the role of key regulators in the maintenance of immune tolerance. Highly powered genetic studies have found and confirmed many new genes outside of the established role of the human leukocyte antigen locus with these diseases, and indicate an essential role of immune response pathways in these diseases. Progress has also been made in identifying new autoantigens and the development of new animal models for the study of endocrine autoimmunity. Finally, although hormone replacement therapy is still likely to be a mainstay of treatment in these disorders, there are new agents being tested for potentially treating and reversing the underlying autoimmune process. CONCLUSION: Although autoimmune endocrine disorders are complex in etiology, these recent advances should help contribute to improved outcomes for patients with, or at risk for, these disorders.
AbstractImmune system homeostasis is tightly maintained by regulatory mechanisms that allow for the destruction of pathologic microorganisms while preventing pathologic inflammation. Disruption of these regulatory mechanisms can lead to immunodeficiency and uncontrolled inflammation as seen in hyper-IgE syndrome and in immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. The discovery of monogenic defects in these disorders has led to a greater understanding of these complex disorders and of the mechanisms underlying immune system regulation.
Laboratory Medicine · 2009 · 2 citations · open access
A Mystery Diagnosis: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Recessive
AbstractImmune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), a rare disease, has recently been shown to occur more frequently than previously suspected. The clinical phenotype of IPEX is a direct result of an overactive immune system caused by the proliferation of autoaggressive T cells and autoantibody-producing B cells. Without prompt diagnosis and treatment, the disease can be fatal within 1 year.
Pediatric Dermatology · 2023 · 1 citations · open access
Infantile vitiligo and alopecia in immunodysregulation polyendocrinopathy enteropathy <scp>X‐linked</scp> syndrome
AbstractImmune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) is characterized by failure to thrive, severe chronic diarrhea, neonatal type 1 diabetes or thyroiditis, and eczematous dermatitis. We report a patient with infantile onset IPEX syndrome who developed vitiligo, alopecia, and chronic diarrhea. Awaiting stem cell transplant, he had multiple episodes of sepsis and succumbed at the age of 10 months. The constellation of symptoms is important to prompt clinicians to suspect this rare syndrome as early hematopoietic stem cell transplantation is the only cure for IPEX patients.
AbstractAutoimmune endocrine disorders are common conditions evaluated for and treated by pediatric endocrinologists. Recognition of the underlying autoimmunity associated with the disorders and disease associations is critical to providing appropriate care for these patients. Autoimmune endocrine disorders coexist in recognized syndromes known as the autoimmune polyendocrine syndromes (APS): APS-1 or autoimmune polyendocrinopathy candidiasis and ectodermal dystrophy (APECED) and APS-2. More rare autoimmune endocrine disorders include the immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome. This rare disorder presents in infancy with type 1 diabetes and enteropathy. In this chapter, we will discuss the pathophysiology of the autoimmune process, the underlying genetics and disease associations of the autoimmune polyendocrine syndromes, and treatment and screening protocols and briefly touch on rare autoimmune endocrine disorders.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
